Press Release: UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

Jun 14, 2019

UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

Read more

Press Release: UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

May 20, 2019

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

Read more

Press Release: UCB to provide additional information to the U.S. FDA regarding midazolam nasal spray submission

Apr 01, 2019

Brussels (Belgium) & Atlanta, Georgia (U.S.) - April 1, 2019: UCB announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter requesting additional information to complete the review of the New Drug Application for midazolam nasal spray, a rescue treatment for acute repetitive seizures (ARS, also known as seizure clusters) in patients with epilepsy. UCB acquired the rights to midazolam nasal spray from Proximagen in June 2018.

Read more

Press Release: CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis

Mar 28, 2019

• Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment

• FDA approval was based on the C-AXSPAND Phase 3 study in adults with non-radiographic axial spondyloarthritis, which demonstrated rapid and major improvement response with CIMZIA compared to placebo. Patients remained on common background medications, which could be adjusted at any point during the study

Read more

Press Release: Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Mar 11, 2019

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Read more

Press Release: UCB Ventures Appoints Alicia Irurzun-Lafitte as Partner

Mar 06, 2019

Read more

Press Release: Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

Mar 02, 2019

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

Read more

Press Release: New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

Mar 01, 2019

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

Read more

Press Release: UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership

Nov 30, 2018

UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership

Read more

UCB First Nine Months Interim Report 2018: UCB tracking well towards full year financial outlook

Oct 30, 2018

UCB tracking well towards full year financial outlook

Read more